Evoke Pharma Acquired by QOL Medical for $11.00 Per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Newsfilter
- Acquisition Completed: QOL Medical successfully acquired Evoke Pharma at $11.00 per share, obtaining approximately 67.63% of the outstanding shares, which marks Evoke as a wholly owned subsidiary and strengthens QOL's position in the rare disease market.
- Transaction Timeline: The tender offer expired on December 15, 2025, without extension, demonstrating QOL Medical's commitment to the acquisition, which is expected to accelerate Evoke's product development and market introduction.
- Market Reaction: Evoke's stock ceased trading on Nasdaq on December 17, 2025, with plans for delisting and deregistration, reflecting positive market expectations for the deal that may enhance QOL Medical's overall market value.
- Strategic Integration: The acquisition incorporates Evoke's GIMOTI product into QOL Medical's portfolio, which is anticipated to enhance service capabilities for rare disease patients through resource and market channel integration, further expanding market share.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
